Zomedica Corp. (ZOMDF)
| Market Cap | 97.44M |
| Revenue (ttm) | 32.03M |
| Net Income (ttm) | -81.86M |
| Shares Out | 979.95M |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,098,111 |
| Average Volume | 1,021,470 |
| Open | 0.0950 |
| Previous Close | 0.0980 |
| Day's Range | 0.0940 - 0.1014 |
| 52-Week Range | 0.0350 - 0.1580 |
| Beta | 1.46 |
| RSI | 38.70 |
| Earnings Date | May 8, 2026 |
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of p... [Read more]
Financial Performance
In 2025, Zomedica's revenue was $32.03 million, an increase of 17.39% compared to the previous year's $27.29 million. Losses were -$81.86 million, 74.2% more than in 2024.
Financial StatementsNews
Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
April session to take investors inside Zomedica's manufacturing operations - showcasing quality systems, automation, and teams driving scalable product fulfillment providing substantial margins ANN AR...
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive recurring diagnostic revenue ANN ARBOR, MI / ACCESS New...
Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity
Zomedica surpasses $10 million in quarterly revenue for the first time and delivers record year-over-year revenue for 20th straight quarter. ANN ARBOR, MI / ACCESS Newswire / March 16, 2026 / Zomedica...
Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor Webinar
Webinar will include a review of full-year 2025 and fourth quarter 2025 financial results, a deep dive into the equine veterinary market and Zomedica's equine-focused product portfolio, along with a l...
Zomedica Transcript: Status update
R&D and product innovation remain central, with TRUFORMA, VetGuardian, and TRUVIEW platforms driving growth and market expansion. Financial performance is improving, with profitability targeted for 2027 and breakeven possible by end of 2026. Human health entry will focus on partnerships and contract manufacturing.
Zomedica Expands Distribution of TRUVIEW(R) Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary Pathology
Partnership Expected to Accelerate System Placements and Support Recurring Consumables Revenue Growth ANN ARBOR, MI / ACCESS Newswire / February 25, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or ...
Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation Pipeline
February session to highlight how Zomedica's R&D strategy supports scalable growth and long-term shareholder value ANN ARBOR, MI / ACCESS Newswire / February 5, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Z...
Zomedica Expands its TRUVIEW(R) Microscopy Platform with AI Diagnostic Interpretation, Growing its Market Opportunity
AI-enabled hematology and cytology analysis improves diagnostic speed, consistency, and workflow efficiency for veterinary clinics ANN ARBOR, MI / ACCESS Newswire / January 23, 2026 / Zomedica Corp. (...
Zomedica Transcript: Status update
Digital innovation and AI are driving growth, with recurring consumable revenue at 70-73% and break-even targeted at $55M annualized revenue by 2027. TRUVIEW AI and PIMS integration are key product milestones, and new TRUFORMA assays will expand market reach in 2026.
Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health
Agreement leverages existing infrastructure to add contract-based revenue, improve asset utilization, support long-term cash flow and create shareholder value through diversified markets ANN ARBOR, MI...
Zomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven Growth
January session to highlight Zomedica's expanding digital capabilities and long-term innovation strategy ANN ARBOR, MI / ACCESS Newswire / January 14, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" o...
Zomedica Launches Next-Generation VETGuardian PLUS(TM) Monitor, Expanding Core Monitoring Platform in Growing Veterinary Market
New platform improves workflow efficiency, strengthens clinical confidence, and supports Zomedica's long-term growth strategy ANN ARBOR, MI / ACCESS Newswire / December 30, 2025 / Zomedica Corp. (OTCQ...
Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv
The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated movie Merv now available on Prime Video ANN ARBOR...
Zomedica Expands TRUFORMA(R) Diagnostic Menu with Launch of Equine Progesterone Assay
Newest assay expands TRUFORMA market opportunity by building on endocrinology foundation to address reproductive health in the equine segment ANN ARBOR, MI / ACCESS Newswire / December 4, 2025 / Zomed...
Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review
November session to provide strategic context for Zomedica's product platforms featured in the previous Fourth Friday at Four Webinars ANN ARBOR, MI / ACCESS Newswire / November 11, 2025 / Zomedica Co...
Zomedica Achieves ISO 13485 Certification, Underscoring Strengthened Quality Infrastructure and Commercial Potential
Certification enhances global market readiness, reinforces quality systems, and supports Zomedica's long-term growth strategy ANN ARBOR, MI / ACCESS Newswire / November 6, 2025 / Zomedica Corp. (OTCQB...
Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth
Zomedica posts highest quarterly revenue ever and record year-over-year revenue for 19th straight quarter! ANN ARBOR, MI / ACCESS Newswire / November 4, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica"...
Zomedica Earnings Call Transcript: Q3 2025
Record Q3 2025 revenue was driven by strong diagnostics and recurring consumables growth, with operating expenses and cash burn significantly reduced. The company is on track for another record quarter, expects to reach cash flow break-even at $55 million revenue, and is launching new products soon.
Zomedica Announces Launch of the Assisi Loop Lounge(R), Scientifically Backed tPEMF(TM) Therapy for Pets
Combining peer-reviewed science, superior comfort, and thoughtful design, the Assisi Loop Lounge expands Zomedica's evidence-based therapeutic portfolio and reinforces Assisi's leadership in targeted ...
Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union
Expanded agreement strengthens Zomedica's European presence, broadens product portfolio on the market, and positions the Company to capture growth in the multi-billion-dollar global veterinary diagnos...
Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October "Fourth Friday at Four" Webinar
Live session on October 24th will showcase how the VETGuardian Monitor enhances patient care, improves workflow efficiency, and expands global market opportunities ANN ARBOR, MI / ACCESS Newswire / Oc...
Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay
First and only in-clinic multiplexed Cobalamin & Folate assay now validated for feline patients ANN ARBOR, MI / ACCESS Newswire / September 23, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "...
Zomedica Expands TRUVIEW(R) and TRUFORMA(R) Intellectual Property Portfolio with Four Newly Issued U.S. Patents
Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the rapidly growing multi-billion dollar veterinary diagn...
Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUVIEW(R) Digital Cytology Microscope - Transforming Veterinary Imaging
Cutting-Edge Digital Microscopy System Featured in Monthly Series Showcasing Innovation in Veterinary Care ANN ARBOR, MI / ACCESS Newswire / September 12, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedic...
Zomedica and UXR Announce Expanded Distribution Agreement in Canada
Agreement strengthens Canadian veterinarians' access to Zomedica's advanced therapeutic and monitoring solutions ANN ARBOR, MI / ACCESS Newswire / September 10, 2025 / Zomedica Corp. (OTCQB:ZOMDF), a ...